INTRODUCTION {#s1}
============

Breast cancer is a heterogeneous disease with different biologic subtypes that are recognized by gene expression profiling studies. Clinically, these subtypes are characterized on the basis of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) is an aggressive subtype that is defined by lack of expression of ER and PR as well as absence of overexpressed or amplified HER2.^[@B1]^ TNBC accounts for approximately 12% to 17% of all invasive breast cancers in Western populations.^[@B1]^ TNBC occurs more frequently in younger women and is associated with higher histologic grade and more advanced disease.^[@B1],[@B2]^ In North America, it is more frequently seen in women of African American ethnicity compared with other ethnic groups.^[@B2]-[@B5]^

Breast cancer is the most common cancer in India.^[@B6]^ For example, in 2012, it is estimated that approximately 145,000 new patients were diagnosed with breast cancer in India, and nearly 70,000 women died of the disease.^[@B7]^ Age-standardized 5-year breast cancer survival for Indian women diagnosed with breast cancer is 60% compared with \> 80% in Western countries.^[@B8]^ Whereas breast cancer incidence seems to be increasing in the country, epidemiology of the disease is inadequately studied.^[@B9]^ Prevalence of TNBC in India is reported to be higher than that observed in Western populations; however, there is considerable variation in prevalence rates reported by studies from the region. It is important to obtain a reliable summary estimate of the prevalence of TNBC in India to address the growing burden of breast cancer in the country. Hence, we conducted a systematic review and literature-based meta-analysis of studies that reported on the prevalence of TNBC in India.

METHODS {#s2}
=======

Search Strategy {#s3}
---------------

Studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015, were identified by using Medline, Scopus, EMBASE, and Web of Science databases (performed by G.S.S. and H.P.). Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed for article search and reporting. Computer-based search used combinations of the following medical subject headings and keywords: triple negative, breast cancer, and India.

Study Eligibility {#s4}
-----------------

We included studies in the meta-analysis if the following criteria were met: provided data on patients with breast cancer in India and described prevalence of triple-negative tumor subtype in the study population. We excluded studies that were comprised of patients with inflammatory breast cancer.

Data Extraction {#s5}
---------------

Two investigators (G.S.S. and A.M.) independently screened all identified titles and abstracts from the search results. We scanned the reference lists of articles for additional articles. Full texts of screened articles were reviewed by G.S.S. and A.M. for inclusion criteria. Disagreements were resolved by consensus. Study selection process and flow diagram for identifying studies is detailed in [Figure 1](#F1){ref-type="fig"}. We extracted relevant information from each study by using a standardized form, which was designed before implementation of the search strategy. The following information was extracted from each article by G.S.S. and A.M.: study design, region, publication year, study year, mean age, stage and grade distribution, receptor status, proportion of patients with ductal histology, proportion of patients with axillary lymph node involvement, proportion of patients who were premenopausal, and method of ER, PR, and HER2 assessment.

![Flow diagram for identifying studies for assessment of prevalence of triple-negative breast cancer in India.](JGO.2016.005397f1){#F1}

Definitions of ER, PR, and HER2 {#s6}
-------------------------------

Level of ER is expressed as a product of the percentage of epithelial cells stained and intensity of staining through immunohistochemistry (IHC). Historically, the cutoff value of ER-positive disease was defined as nuclear staining of ≥10% of the epithelial component of the tumor; however, in 2010 ASCO lowered the IHC cutoff for determining ER-positive status from the previous value of 10% to 1% of stained cells.^[@B10]^ This was based on the finding that even tumors weakly staining in 1% to 10% of cells demonstrated objective clinical benefit from treatment with tamoxifen.^[@B11]^ We extracted data on definitions of ER and PR positivity (≥ 1% or ≥ 10% or not reported).

With regard to HER2 testing, ASCO released an algorithm that defined positive, equivocal, and negative values for both HER2 protein expression and gene amplification. A positive HER2 result is IHC staining of 3+ (uniform, intense membrane staining of \> 30% of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus, or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2. A negative result is an IHC staining of 0 or 1+, a FISH result of fewer than 4.0 HER2 gene copies per nucleus, or a FISH ratio of less than 1.8.^[@B12]^ Equivocal results (IHC staining of 2+) require additional testing for final classification. We extracted data on HER2 assessment method; studies that considered an IHC score of 2+ and 3+ as positive for HER2, studies that considered an IHC score of 3+ alone as positive for HER2, studies that used FISH test in patients who had 2+ score by IHC, and studies that did not disclose the method of checking HER2 status.

Only studies that reported on all three receptors (ER, PR, HER2) or those that reported on the proportion of TNBC were included in analyses. In some studies, more patients had data on ER or PR status than on HER2. Hence, in those studies, denominators were changed accordingly to provide an accurate assessment of the prevalence of hormone receptor (HR)--positive disease (defined as ER-positive and/or PR-positive), HER2-positive disease, or TNBC.

Assessment of Study Quality {#s7}
---------------------------

We used STROBE statement guidelines to assess quality of selected studies.^[@B13]^ One point each was given if the study described the setting and study participants, reported descriptive data, provided detailed outcome data, and discussed limitations, for a maximum score of 5 and a minimum of zero. We performed subgroup analysis stratified by study quality score of ≥ 4 versus \< 4.

Statistical Analysis {#s8}
--------------------

Standard errors for study-specific prevalence estimates were determined from the point estimate and appropriate denominators, assuming a binomial distribution. To obtain an overall summary estimate of prevalence across studies, we pooled study-specific estimates by using a random-effects model meta-analysis. We also performed a fixed-effect model meta-analysis for comparison. Between-study heterogeneity was quantified by using I^2^ statistics. The I^2^ statistic estimates percentage of total variation across studies that are the result of true between-study differences rather than chance. We explored sources of heterogeneity by using subgroup analyses and metaregression. We assessed publication bias by using funnel plot symmetry and Egger regression intercept. All analyses were performed using STATA software (v13; STATA, College Station, TX; Computing Resource Center, Santa Monica, CA). Statistical tests were two-sided, and *P* \< .05 was considered statistically significant.

RESULTS {#s9}
=======

Study Characteristics {#s10}
---------------------

Seventeen cross-sectional studies that involving 7,237 patients with breast cancer were included in this review ([Table 1](#T1){ref-type="table"}).^[@B14]-[@B30]^ Mean age of patients ranged from 43 to 55 years across studies, with a weighted average of age 50 years. Proportion of patients who were premenopausal ranged from 27% to 67% across studies, with a weighted average of 41%. Proportion of patients with grade 3 disease ranged from 16% to 75%, with a weighted average of 57%; corresponding figures for patients with tumor size \> 5 cm were 3% to 65% (weighted average, 24%) and those for patients with positive axillary lymph nodes were 39% to 90% (weighted average, 57%). Prevalence estimates of HR-positive disease, HER2-positive disease, and TNBC in each of the included studies are reported in [Table 1](#T1){ref-type="table"}.

###### 

Study Characteristics of 17 Cross-Sectional Studies Included in the Meta-Analysis, and Prevalence of HR-Positive Disease, HER2-Positive Disease, and TNBC in These Studies

![](JGO.2016.005397t1)

Prevalence of TNBC {#s11}
------------------

Overall combined prevalence of TNBC in the random-effects model meta-analysis was 31% (95% CI, 27% to 35%). Pooled estimate from the fixed-effect model meta-analyses was comparable ([Fig 2](#F2){ref-type="fig"}). There was substantial heterogeneity across the studies (I^2^ of 91.2% \[95% CI, 88% to 94%\]; *P* \< .001). Sources of heterogeneity were explored by several study-level characteristics, as described in Prevalence of TNBC by Study-level Characteristics. Overall combined prevalence of HR-positive breast cancer was 48% (95% CI, 42% to 54%; [Fig 3](#F3){ref-type="fig"}), and overall combined prevalence of HER2-positive breast cancer was 27% (95% CI, 24% to 31%; [Fig 4](#F4){ref-type="fig"}).

![Prevalence of triple-negative breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.](JGO.2016.005397f2){#F2}

![Prevalence of hormone receptor--positive breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.](JGO.2016.005397f3){#F3}

![Prevalence of human epidermal growth factor receptor 2--positive breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.](JGO.2016.005397f4){#F4}

Prevalence of TNBC by Study-Level Characteristics {#s12}
-------------------------------------------------

In an attempt to explain heterogeneity, we performed subgroup analysis and metaregression by using several study-level characteristics ([Fig 5](#F5){ref-type="fig"}). Meta-analysis included four studies each from the north, east, and west of the country and five studies from the south. We found no significant difference in prevalence of TNBC by region. Overall prevalence of TNBC in the north, south, east, and west of the country was 28%, 34%, 30%, and 31%, respectively. Heterogeneity in overall prevalence of TNBC was not explained by other available study-level characteristics, such as mean age of participants or proportion of patients who were premenopausal, had grade 3 disease, or had tumor size \> 5 cm.

![Prevalence of triple negative breast cancer by various study characteristics. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.](JGO.2016.005397f5){#F5}

Definition of ER, PR, and HER2 {#s13}
------------------------------

Definition of HR and HER2 was variable across studies ([Table 1](#T1){ref-type="table"}). Nine studies defined HR-positive as ER and PR ≥ 1% and four studies defined HR-positive as ER and PR ≥ 10%, whereas four studies did not describe the definition of HR. Nine studies defined HER2-positive status as only 3+ by IHC (Doval et al^[@B17]^ used FISH test to classify equivocal cases and is therefore included in the 3+ group) and five studies included 2+ as positive, whereas three studies did not describe the definition of HER2. We did not find significant difference in pooled estimates subgrouped by different definitions for HR and HER2 ([Fig 5](#F5){ref-type="fig"}).

Study Quality {#s14}
-------------

One study scored the maximum score of 5, 11 studies scored 4, four studies scored 3, and one study scored 2 on assessment of study quality. Lower quality studies (study quality score \< 4) had a tendency to report higher prevalence of TNBC compared with higher quality studies (score ≥ 4); 38% \[95% CI, 27% to 48%\] versus 29% \[95% CI, 25% to 33%\], respectively, although confidence intervals overlap (*P* = .12; [Fig 5](#F5){ref-type="fig"}).

Assessment of Publication Bias {#s15}
------------------------------

There was no evidence of publication bias by visual inspection of funnel plot or Egger test for bias (*P* = .24; Appendix [Fig A1](#FA.1){ref-type="fig"}). Furthermore, pooled estimate from larger-sized studies (N ≥ 250), which are less likely to be subjected to publication bias, with that from smaller-sized studies (N \< 250) were comparable (29% \[95% CI, 25% to 32%\] versus 34% \[95% CI, 25% to 43%\]; *P* = .34; [Fig 4](#F4){ref-type="fig"}).

Sensitivity Analysis {#s16}
--------------------

Rao et al^[@B28]^ described a low prevalence of HER2-positive disease (2.4%; n = 126). Prevalence of TNBC in this study was 50%. Such a low rate of HER2-positive disease has not been reported from India or elsewhere; however, a sensitivity analysis performed after omitting data from the study yielded results that were similar to the main analyses.

DISCUSSION {#s17}
==========

To our knowledge, this systematic review and meta-analysis of 17 cross-sectional studies that involved 7,237 patients with breast cancer is the most comprehensive analysis on prevalence of TNBC in India. Prevalence of TNBC in India ranged from 27% to 35% across studies, with a summary estimate of 31%. This is comparable to the prevalence seen in African American women and is more than twice the rate seen in white women.^[@B5],[@B31]-[@B34]^ Our study also found a higher prevalence of premenopausal breast cancer, grade 3 disease, and larger tumor size, all of which are associated with triple-negative disease.^[@B1]-[@B3]^ Because TNBC is known to be more aggressive than other breast cancer subtypes, higher prevalence of TNBC could be a contributing factor to the high fatality rate of patients with breast cancer in India.

We explored sources of heterogeneity through subgroup analyses by using study-level characteristics that are known to be associated with a higher prevalence of TNBC, but results were not statistically significant. We also analyzed data on the basis of study location and found similar prevalence rates for TNBC in all four regions in India. We also found that differences in definitions of HR and HER2 positivity did not influence study results.

One limitation of the present meta-analysis is the presence of substantial heterogeneity across the contributing studies that is unexplained by available study-level characteristics; however, similarity of findings from pooled estimates from random-effects and fixed-effect models is reassuring. Furthermore, pooled estimates from the small- and larger-sized studies were comparable. India is a vast country with significant variations in linguistic, geographic, dietary, cultural, and health care--associated practices; therefore, one can postulate the presence of considerable inherent heterogeneity at state level that was not captured by regional compartmentalization. Second, we did not incorporate quality scores into meta-analysis weights. An analysis by study quality suggested a higher prevalence of TNBC in lower-quality studies; however, difference in prevalence rates by study quality was not statistically significant. Third, the contributing study results are subjected to local laboratory standards and practices. Fourth, primary data are obtained from studies that were conducted at various tertiary-level hospitals, which could result in an inherent selection bias as a result of the possibility that patients who have more advanced disease could be selectively referred to such institutions. However, most cancer care in India occurs in tertiary-level institutions, and, therefore, we do not think the actual prevalence rate will be significantly different from that identified in our meta-analysis. Finally, several potential risk factors, such as obesity, parity, and socioeconomic factors, have not been described in the studies that are included in this meta-analysis.

Multiple factors may account for higher prevalence of TNBC reported by studies conducted among Indian patients with breast cancer. The early age of onset of breast cancer; lifestyle factors, such as diet and obesity; reproductive factors, such as multiparity; socioeconomic status; and screening behaviors may be hypothesized as probable etiology.^[@B2],[@B3]^ Another important factor could be a potential genetic susceptibility of Indians to TNBC. More focused research into these factors will help clarify underlying determinants of TNBC in India. A first step in this direction would be to institute a prospectively managed, population-based database of patients with breast cancer, along with reliable histopathologic testing.

In conclusion, this systematic review and meta-analysis demonstrated a high prevalence rate of TNBC in India. Further research to identify the determinants of such a high prevalence of TNBC is warranted as they may have implications for addressing the burden of breast cancer mortality in India.
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